Saladin M, Gray K, McRae-Clark A, LaRowe S, Yeatts S, Baker N
Psychopharmacology (Berl). 2013; 226(4):721-37.
PMID: 23460266
PMC: 3637960.
DOI: 10.1007/s00213-013-3039-3.
Witte D, Ensing K, Franke J, de Zeeuw R
Pharm World Sci. 1993; 15(1):10-6.
PMID: 8485501
DOI: 10.1007/BF02116164.
Borgstrom L, Johansson C, Larsson H, Lenander R
J Pharmacokinet Biopharm. 1981; 9(4):419-29.
PMID: 7310641
DOI: 10.1007/BF01060886.
von Bahr C, Hermansson J, Tawara K
Br J Clin Pharmacol. 1982; 14(1):79-82.
PMID: 7104170
PMC: 1427572.
DOI: 10.1111/j.1365-2125.1982.tb04937.x.
Sheiner L, Benet L, Pagliaro L
J Pharmacokinet Biopharm. 1981; 9(1):59-127.
PMID: 7014827
DOI: 10.1007/BF01059343.
Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients.
Tawara K, Kawashima K, Ishikawa H, Yamamoto K, Saito K, Ebihara A
Eur J Clin Pharmacol. 1981; 19(3):197-203.
PMID: 6894282
DOI: 10.1007/BF00561949.
Stereoselective binding of propranolol enantiomers to human alpha 1-acid glycoprotein and human plasma.
Albani F, Riva R, Contin M, Baruzzi A
Br J Clin Pharmacol. 1984; 18(2):244-6.
PMID: 6487464
PMC: 1463537.
DOI: 10.1111/j.1365-2125.1984.tb02462.x.
Simple and reliable radioreceptor assay for beta-adrenoceptor antagonists and active metabolites in native human plasma.
Wellstein A, Palm D, Wiemer G, Schafer-Korting M, Mutschler E
Eur J Clin Pharmacol. 1984; 27(5):545-53.
PMID: 6151508
DOI: 10.1007/BF00556890.
Kinetics and metabolism of (+)-, (-)- and (+/-)-bufuralol.
Francis R, East P, Larman J
Eur J Clin Pharmacol. 1982; 23(6):529-33.
PMID: 6130953
DOI: 10.1007/BF00637501.
Pharmacokinetics of pindolol in man.
Gugler R, Herold W, DENGLER H
Eur J Clin Pharmacol. 1974; 7(1):17-24.
PMID: 4853602
DOI: 10.1007/BF00614385.
Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.
Lewis R, TRAGER W, Chan K, Breckenridge A, Orme M, Roland M
J Clin Invest. 1974; 53(6):1607-17.
PMID: 4830225
PMC: 302656.
DOI: 10.1172/JCI107711.
Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs.
SHAND D
Drugs. 1974; 7(1):39-47.
PMID: 4151694
DOI: 10.2165/00003495-197407010-00003.
Contribution of the liver to overall elimination of propranolol.
George C, Orme M, Buranapong P, MacErlean D, Breckenridge A, Dollery C
J Pharmacokinet Biopharm. 1976; 4(1):17-27.
PMID: 1271238
DOI: 10.1007/BF01271441.
Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.
Pagliaro L, Benet L
J Pharmacokinet Biopharm. 1975; 3(5):333-83.
PMID: 1107513
DOI: 10.1007/BF01082306.
A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol.
Branch R, James J, Read A
Br J Clin Pharmacol. 1976; 3(2):243-9.
PMID: 973958
PMC: 1428884.
DOI: 10.1111/j.1365-2125.1976.tb00599.x.
Oral anticoagulants--the totem and the taboo.
Breckenridge A
Br Med J. 1976; 1(6007):419-23.
PMID: 766893
PMC: 1638959.
DOI: 10.1136/bmj.1.6007.419.
The assessment of beta-adrenoceptor blocking drugs in man.
McDevitt D
Br J Clin Pharmacol. 1977; 4(4):413-25.
PMID: 20123
PMC: 1429044.
DOI: 10.1111/j.1365-2125.1977.tb00756.x.
Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
Johnsson G, Regardh C
Clin Pharmacokinet. 1976; 1(4):233-63.
PMID: 13958
DOI: 10.2165/00003088-197601040-00001.
Altered hepatic blood flow and drug disposition.
Nies A, SHAND D, Wilkinson G
Clin Pharmacokinet. 1976; 1(2):135-55.
PMID: 13954
DOI: 10.2165/00003088-197601020-00005.
Clinical pharmacokinetics of beta-adrenoreceptors blockers.
Johnsson G, Regardh C
Drugs. 1976; 11 SUPPL 1:111-21.
PMID: 6243
DOI: 10.2165/00003495-197600111-00026.
